MYCN amplification is a powerful prognostic factor for NBs regardless of other factors, such as age, staging, INPC, and genetic aberrations of 1p and 11q, and it has appeared in approximately 20% of NBs and about 38% of all stage 4 patients (Berthold et al., 2017; Maris, 2010). Here, MYCN is linked to Nijmegen breakage syndrome.